The 14 most recent market catalysts affecting $KURA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 55
J.P. Morgan Analyst Raises Kura Oncology Price Target to $32
J.P. Morgan analyst Priyanka Grover has raised her price target for Kura Oncology from $30 to $32, reaffirming a bullish rating. This action signals increased confidence from a maj…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 85
Kura Oncology Reports Third Quarter 2026 Financial Results
Kura Oncology's 8-K filing details impressive third-quarter 2026 financial results, primarily driven by the strong commercial performance of its FDA-approved menin inhibitor, KOMZI…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Kura Oncology and Kyowa Kirin Announce Acceptance of Eight Abstracts for 2026 ASH Annual Meeting
Kura Oncology and its partner Kyowa Kirin have secured eight abstract acceptances, including four oral presentations, for their drug candidate ziftomenib at the prestigious 2026 AS…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
Kura Oncology to Report Third Quarter 2026 Financial Results on November 10
This 8-K filing from Kura Oncology, Inc. is a standard announcement regarding the scheduling of its third-quarter 2026 financial results release and subsequent investor call. It ma…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 65
Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
Caspian Therapeutics and Kura Oncology are holding a webcast to discuss the development strategy for KO-7246, a novel oral menin inhibitor. This event is significant because it wil…
Oct 1, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
JP Morgan's initiation of coverage on Kura Oncology with an 'Overweight' rating and a $30 price target is a positive development for the company. Analyst coverage, especially from …
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 65
Caspian Therapeutics And Kura Oncology Released Comprehensive Preclinical Data Supporting KO-7246 For Diabetes
Kura Oncology and Caspian Therapeutics released comprehensive preclinical data for KO-7246, a menin inhibitor designed to treat Type 1 and Type 2 diabetes. The data indicates that …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Kura Oncology shares are trading higher after a Form 4 filing indicated that CEO Troy Wilson bought 100,000 shares at an average price of $12.39 per share.
The CEO's purchase of 100,000 shares at a significant price point is a strong signal of insider confidence in Kura Oncology's prospects. This often translates to positive investor …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Kura Oncology shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Wedbush maintained an Outperform rating on the stock and raised its price target from $36 to $38.
This headline is a strong positive catalyst for Kura Oncology. The better-than-expected Q2 EPS results demonstrate fundamental strength and operational efficiency, while Wedbush's …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38
Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating for Kura Oncology and raised the price target from $36 to $38. This action signals a positive outlook from a p…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate
Kura Oncology's Q2 earnings report presents a mixed bag for investors. While the company successfully beat EPS estimates, indicating better-than-expected cost management or other f…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 65
Kura Oncology Announces Publication Of Manuscript In Blood, Journal Of The American Society Of Hematology, Detailing Discovery And Preclinical Development Of Ziftomenib
Kura Oncology announced the publication of a manuscript in 'Blood' detailing the discovery and preclinical development of ziftomenib, a drug already approved by the FDA in 2025 for…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
Kura Oncology Announces Updated Phase 1A Results From Ongoing FIT-001 Clinical Trial; Data Demonstrate Encouraging And Durable Clinical Activity Of Darlifarnib Plus Cabozantinib In Cabozantinib-Naïve Patients With Advanced Clear Cell Renal Cell Carcinoma
Kura Oncology released updated Phase 1A results from its FIT-001 clinical trial, highlighting encouraging and durable clinical activity of darlifarnib combined with cabozantinib in…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 65
Kura Oncology To Feature Updated Phase 1a Results From Ongoing FIT-001 Phase 1a/1b Clinical Trial Evaluating Darlifarnib In Combination With Cabozantinib In Advanced Renal Cell Carcinoma In Oral Presentation At 2026 KCRS
Kura Oncology is announcing an upcoming oral presentation at the 2026 Kidney Cancer Research Summit (KCRS) featuring updated Phase 1a results from its FIT-001 clinical trial. This …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.